History and new developments: Pharmacology of 5-HT3 antagonists;Historie und neue entwicklungen: Pharmakologie der 5-HT3- antagonisten

Pharmazie in Unserer Zeit

Volumn 36, Issue 5, 2007, Pages 342-353

  Rex, André ^b   Bert, Bettina ^b   Fink, Heidrun ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; DOLASETRON MESILATE; FLUOXETINE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; PALONOSETRON; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN RECEPTOR; TROPISETRON;

DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; REVIEW; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIEMETICS; ANXIETY; DOPAMINE; DYSPEPSIA; HISTORY, 20TH CENTURY; HUMANS; LEARNING; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 34948845664     PISSN: 00483664     EISSN: 16151003     Source Type: Journal    
DOI: 10.1002/pauz.200700230     Document Type: Review

References (32)

1. Rapport, M.: The discovery of serotonin. Perspect. Biol. Med. 4 (1997), 260-273.
2. Hoyer, D., Hannon, J.P., Martin, G.R.: Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71 (2002), 533-554.
3. Kilpatrick, C.J., Tyers, M.B.: The pharmacological properties and functional roles of central 5-HT3 receptors. In: Central and peripheral 5-HT3 receptors. Hamon, M. (Eds.) Academic Press. (1992), pp. 33-57.
4. Buchheit, K.H., Costall, B., Engel, G., Gunning, S.J., Naylor, R.J., Richardson, B.P.: 5-Hydroxytryptamine receptor antagonism by metoclopramide and ICS 205-930 in the guinea-pig leads to enhancement of contractions of stomach muscle strips induced by electrical field stimulation and facilitation of gastric emptying in-vivo. J. Pharm. Pharmacol. 37 (1985), 664-667.
5. Butler, A., Hill, J.M., Ireland, S.J., Jordan, C.C., Tyers, M.B.: Pharmacological properties of CR38032F, a novel antagonist at 5-HT3 receptors. Br. J. Pharmacol. 94 (1988), 397-412.
6. Fozard, J.R.: 5-HT: the enigma variations. Trends Pharmacol. Sci. 8 (1987), 501-506.
7. Engel, G., Richardson, B.P., Donatsch, P., Stadler, P.: Eine neue Wirkstoffklasse: 5-HT3-Rezeptorantagonisten. TRIANGEL 25 (1986), 123-130.
8. Simon, B., Müller, P.: 5-HT3-Antagonisten gegen Erbrechen und Unwohlsein nach Zytostatika. Deutsches Ärzteblatt 87 (1990), 1960-1961.
9. Dubin, A.E., Huvar, R., D'Andrea, M.R., Pyati, J., Zhu, J.Y., Joy, K.C., Wilson, S.J., Calindo, J.E., Class, C.A., Luo, L., Jackson, M.R., Lovenberg, T.W., Erlander, M.G.: The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J. Biol. Chem. 274 (1999), 30799-30810.
10. Thompson, A.J., Lummis, S.C.: 5-HT3 receptors. Curr. Pharm. Des. 12 (2006), 3615-3630.
11. Melis, C., Chau, P.L., Price, K.L., Lummis, S.C., Molteni, C.: Exploring the binding of serotonin to the 5-HT3 receptor by density functional theory. J. Phys. Chem. B 110 (2006), 26313-26319.
12. Jensen, T.N., Nielsen, J., Frederiksen, K., Ebert, B.: Molecular cloning and pharmacological characterization of serotonin 5-HT(3A) receptor subtype in dog. Eur. J. Pharmacol. 538 (2006), 23-31.
13. Aapro, M.: 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 69 (2005), 97-109.
14. Tonini, M., Pace, F.: Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig. Dis. 24 (2006), 59-69.
15. Savastano, D.M., Hayes, M.R., Covasa, M.: Serotonin-type 3 receptors mediate intestinal lipid-induced satiation and Fos-like immunoreactivity in the dorsal hindbrain. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006).
16. Nakade, Y., Fukuda, H., Iwa, M., Tsukamoto, K., Yanagi, H., Yamamura, T., Mantyh, C., Pappas, T.N., Takahashi, T.: Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats. Am. J. Physiol. Gastrointest. Liver. Physiol. (2006).
17. Jordan, K., Hinke, A., Grothey, A., Voigt, W., Arnold, D., Wolf, H.H., Schmoll, H.J.: A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer (2007).
18. McNulty, R.: Are All 5-HT3 Receptor Antagonists the Same? J. Natl. Compr. Canc. Netw. 5 (2007), 35-43.
19. De Leon, A.: Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting. Proc. (Bayl. Univ. Med. Cent.) 19 (2006), 413-416.
20. Hesketh, P.J.: New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 12 (2004), 550-554.
21. Eisenberg, P., MacKintosh, F.R., Ritch, P., Cornett, P.A., Macciocchi, A.: Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann. Oncol. 15 (2004), 330-337.
22. Rubenstein, E.B., Slusher, B.S., Rojas, C., Navari, R.M.: New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 12 (2006), 341-347.
23. Navari, R.M.: Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol. 2 (2006), 591-602.
24. Eberhart, L., Morin, M., Geldner, G., Wulf, H.: Minimierung von Überlkeit und Erbrechen in der postoperativen Phase. Deutsches Ärzteblatt 100 (2003), 2154-2160.
25. Tack, J., Fried, M., Houghton, L.A., Spicak, J., Fisher, G.: Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Aliment. Pharmacol. Ther. 24 (2006), 183-205.
26. McLean, P.C., Borman, R.A., Lee, K.: 5-HT in the enteric nervous system: gut function and neuropharmacology. Trends Neurosci. 30 (2007), 9-13.
27. Riering, K., Rewerts, C., Zieglgänsberger, W.: Analgesic effects of 5-HT3 receptor antagonists. Scand. J. Rheumatol. Suppl. (2004), 19-23.
28. Giordano, J., Schultea, T.: Serotonin 5-HT3 Receptor Mediation of Pain and Anti-Nociception: Implications for Clinical Therapeutics. Pain Physician 7 (2004), 141-147.
29. Muller, W., Fiebich, B.L., Stratz, T.: 5-HT3 receptor antagonists als analgetics in rheumatic diseases. Z. Rheumatol. (2006),
30. Farber, L., Haus, U., Spath, M., Drechsler, S.: Physiology and pathophysiology of the 5-HT3 receptor. Scand. J. Rheumatol. Suppl. (2004), 2-8.
31. Teitler, M., Herrick-Davis, K.: Multiple serotonin receptor subtypes: molecular cloning and functional expression. Crit. Rev. Neurobiol. 8 (1994), 175-188.
32. Jackson, M.B., Yakel, J.L.: The 5-HT3 receptor channel. Annu. Rev. Physiol. 57 (1995), 447-468.